

B3
conced

46. The method according to claim 45 wherein said tumor is breast cancer.

47. The therapeutic method of claim 16 wherein said drugs are natural or synthetic.--

REMARKS

Claims 20, 22, and 23 have been amended. Claim 20 has been amended to remove an aspect of the claim which is the subject of new claims 37-39. Claims 22 and 23 have been amended to correct dependency from claim 16 to claim 21. Entry of the amended claims is respectfully requested.

Applicants acknowledge with appreciation the telephonic discussion with Examiner Johnson on June 2, 1999. The discussion centered around the omission of the "drug" aspect of claims 1 and 16 in the grouping of the claims. Furthermore, though not discussed in the interview, Applicants found that the "natural or synthetic inhibitor of PBR" aspect of claim 20 was also not included in any of the invention groups. New claims 37-39 and 47 are drawn to a composition comprising a natural or synthetic inhibitor of PBR and method of use, and new claims 43-46 are drawn to a composition comprising a natural or synthetic drug and method of use. Support for the new claims is found throughout the specification and in the claims as originally filed. Entry of the new claims and reconsideration of the restriction


requirement are respectfully requested in light of the omissions and in light of the amended and new claims.

Applicants hereby elect, with traverse, the invention of Group III, claims 1, 4, and 20 drawn to antagonists of PBR. Applicants would like the opportunity to reconsider this election should the restriction requirement be reconsidered or restated. Applicants submit that newly added claims 40-42 drawn to a composition comprising a PBR antagonist and method of using same and are believed to fall within the elected group of claims, i.e. Group III. Entry of new claims 40-42 is respectfully requested.

Applicants request that the specific method groups that call on a product be rejoined should the claims for the product be allowable.

In re Application of Papadopoulos and Culy
Serial no. 09/047,652

An early and favorable response is respectfully
solicited.


By 
Sana A. Pratt
Reg. No. 39,441

Pratt & Associates, Inc.
10821 Hillbrooke Lane
Potomac, Maryland 20854
(301) 294-9171

I hereby certify that this correspondence is being
deposited with the United States Postal Service with
sufficient postage as first class mail in an envelope
addressed to the

Commissioner of Patents
Washington, D.C. 20231

on June 14, 1999.

By 
Sana A. Pratt
Reg. No. 39,441